PR99941

Bugworks Research Inc. to Present Eight Posters at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) 2023, in Copenhagen, Denmark

BANGALORE, DELAWARE CITY and ADELAIDE, April 17, 2023 /PRNewswire=KYODO JBN/ --

    Bugworks Research Inc., a clinical-stage biopharmaceutical company, is set

to present its latest research findings on the novel bacterial topoisomerase

inhibitor, BWC0977 at the upcoming 33rd European Congress of Clinical

Microbiology & Infectious Diseases (ECCMID) in Copenhagen, Denmark.

    The eight posters highlight data from the microbiological and efficacy

studies of the clinical candidate, BWC0977 that exhibits broad-spectrum

activity against a globally, diverse panel of Gram-positive, Gram-negative and

biothreat pathogens.  Additionally, data from a range of studies, including in

vitro biochemical assays, in vitro resistance frequency studies, minimum

inhibitory concentration (MIC90) data against multi-drug resistant clinical

isolates from around the world, and in vivo efficacy data in mice and rat

models of infection will be presented.

    These studies were conducted in collaboration with scientists at the Walter

Reed Army Institute of Research (WRAIR), Bethesda, USA, University of

Liverpool, United Kingdom, University of Texas Medical Branch, USA,

International Health Management Associates (IHMA), USA and TheraIndx

Lifesciences Pvt. Ltd., India.  

    "ECCMID 2023 is a globally renowned platform in Infectious Diseases R&D

arena, and we are proud to have the opportunity to showcase the pre-clinical

highlights of our drug candidate BWC0977; a first-of-its-kind in over six

decades that has the potential to treat an entire gamut of infections caused by

hard-to-treat Gram-negative and Gram-positive bacterial pathogens," says Dr.

Vasanthi Ramachandran, Vice President - Collaborations, Bugworks Research India.

Bugworks Research is at the forefront of developing novel antibiotics to combat

the growing threat of antimicrobial resistance. The company's cutting-edge

research is focused on discovering and developing small molecule drugs that

target bacterial enzymes essential for their survival.

    The ECCMID conference is a leading global forum for infectious diseases and

clinical microbiology. Bugworks Research's presentations will take place on

April 17th, 2023, during the poster session. Attendees are invited to visit the

Bugworks Research booth to learn more about the company's innovative approach

to fighting antibiotic resistance.

    About Bugworks

    Bugworks Research Inc, (Bugworks), is a clinical stage biopharmaceutical

company, that is developing novel multi target therapeutic assets in the

anti-infectives and immuno-oncology (IO) areas by integrating the latest

innovations in computational biology, pharmacology, structural-biology, and

medicinal chemistry. BWC0977 is currently in a Phase 1 clinical trial and is

targeted to address unmet needs of serious hospital & community infections, and

bacterial biothreats. Its asset for IO is in the late pre-clinical stage,

targets multiple cancers and is expected to be used either as standalone or in

combination with immune checkpoint therapies.

    For further information, please visit www.bugworksresearch.com

    Logo: https://mma.prnewswire.com/media/1491889/Bugworks_Logo.jpg

    Source: Bugworks